International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 04 Issue 05 May 2024

Page No: 831-834

DOI: https://doi.org/10.47191/ijmscrs/v4-i05-09, Impact Factor: 7.949

# Endocardial Fibroelastosis: A Comprehensive Review of Pathogenesis, Clinical Manifestations, Diagnostic Modalities, and Management Strategies

**Donaldo Emiliano Silva López[1], Oyuky Yumary Citlalli Flores Alamos[2], Saúl Villaseñor Angulo[2], Diana Marisol Perales Rivera[1], Verónica Guadalupe Vázquez Rubio[2], Domingo Antonio Manriquez Vazquez[3]**

[1]Hospital Centenario Miguel Hidalgo. Aguascalientes, Aguascalientes, Mexico.

[2]Hospital Civil de Guadalajara. Guadalajara, Jalisco, México.

[3]Hospital Regional de Alta especialidad de Ciudad Victoria, Tamaulipas, México.

**ABSTRACT**

Endocardial fibroelastosis (EFE) is a rare and enigmatic myocardial disease characterized by the abnormal accumulation of collagen and elastin fibers in the endocardium, predominantly affecting the left ventricle. This comprehensive review aims to elucidate the pathogenesis, clinical manifestations, diagnostic modalities, and management strategies of EFE. EFE typically presents in infants and young children, although adult cases have been reported. The etiology of EFE remains elusive, with theories implicating genetic, infectious, and autoimmune factors. Clinically, EFE may manifest with symptoms of heart failure, arrhythmias, or sudden cardiac death. Diagnosis often involves echocardiography, cardiac magnetic resonance imaging, and endomyocardial biopsy. Management strategies for EFE are primarily supportive, focusing on the management of heart failure symptoms and arrhythmias, with advanced cases necessitating heart transplantation. This review provides a comprehensive overview of EFE, highlighting the challenges in diagnosis and management and underscoring the need for further research to elucidate its pathogenesis and improve outcomes.

**KEYWORDS:** endocardial, fibroelastosis, disease, collagen.

**ARTICLE DETAILS**

**Published On:**
**14 May 2024**

**Available on:**
**https://ijmscr.org/**

## INTRODUCTION

Endocardial fibroelastosis (EFE) is a rare myocardial disease characterized by the abnormal proliferation of collagen and elastin fibers in the endocardium, leading to ventricular stiffness and impaired cardiac function. First described in the early 20th century, EFE primarily affects the left ventricle, although involvement of the right ventricle and atria has been reported. The pathogenesis of EFE remains incompletely understood, with various hypotheses proposed, including genetic mutations, viral infections, and autoimmune reactions. EFE predominantly presents in infants and young children, often leading to congestive heart failure and high mortality rates if left untreated. 1,2

Despite advancements in diagnostic modalities and treatment options, the prognosis for EFE remains guarded, particularly in cases of severe ventricular dysfunction. This review aims to provide a comprehensive overview of EFE, including its pathogenesis, clinical manifestations, diagnostic approaches, and current management strategies, with a focus on highlighting the challenges and future directions in the management of this rare and intriguing myocardial disease.2,3

## EPIDEMIOLOGY OF ENDOCARDIAL FIBROELASTOSIS

Endocardial fibroelastosis (EFE) is a rare myocardial disorder, predominantly affecting infants and young children, although cases in adults have been documented. The exact incidence and prevalence of EFE are challenging to ascertain due to its rarity and the lack of large-scale epidemiological studies. EFE is considered a rare disease, with an estimated incidence of 0.3-0.4 cases per 100,000 live births.2,3

The disease appears to have a slight male predominance, with some studies suggesting a male-to-female ratio of approximately 1.5:1. EFE is reported to be more common in

certain populations, such as individuals of African descent, although the reasons for this are not well understood.3,4

EFE may present as an isolated cardiac anomaly or as part of a broader syndrome, such as Holt-Oram syndrome or LEOPARD syndrome, further complicating the epidemiological picture. The prognosis of EFE varies widely, depending on factors such as the extent of myocardial involvement, the presence of associated anomalies, and the age at diagnosis. Early detection and management are crucial in improving outcomes for patients with EFE.3,4

Overall, EFE remains a rare and challenging disease, necessitating further research to elucidate its epidemiology and improve diagnostic and therapeutic strategies.

## CLINICAL MANIFESTATIONS OF ENDOCARDIAL FIBROELASTOSIS

Endocardial fibroelastosis (EFE) presents with a spectrum of clinical manifestations, ranging from asymptomatic to severe heart failure and arrhythmias. The clinical course of EFE can vary widely, depending on the extent of myocardial involvement and the presence of associated cardiac anomalies.4,5

In infants and young children, EFE often presents with symptoms of congestive heart failure, including tachypnea, poor feeding, failure to thrive, and irritability. These symptoms may be nonspecific and overlap with other causes of heart failure in this age group. Physical examination may reveal signs of congestive heart failure, such as tachycardia, hepatomegaly, and a gallop rhythm.4,5

Arrhythmias are also common in patients with EFE, particularly ventricular arrhythmias, which can lead to syncope or sudden cardiac death. Atrial arrhythmias, such as atrial fibrillation, may also occur, especially in older patients with longstanding disease.5,6

In some cases, EFE may be detected incidentally on imaging studies performed for other reasons. Echocardiography is the primary imaging modality used to diagnose EFE, typically showing thickening of the endocardium and a "ground glass" appearance of the myocardium. Cardiac magnetic resonance imaging (MRI) can provide further characterization of the myocardial tissue and help differentiate EFE from other causes of myocardial thickening. 6,7

Endomyocardial biopsy remains the gold standard for diagnosing EFE, although it is invasive and not routinely performed. Histologically, EFE is characterized by fibroelastic thickening of the endocardium, with variable infiltration of inflammatory cells.6

Overall, the clinical manifestations of EFE are varied and nonspecific, often requiring a high index of suspicion for diagnosis. Early recognition and management of EFE are essential to improve outcomes and prevent complications such as heart failure and arrhythmias.6

## DIAGNOSIS OF ENDOCARDIAL FIBROELASTOSIS

Diagnosing endocardial fibroelastosis (EFE) can be challenging due to its rarity and the nonspecific nature of its clinical presentation. A comprehensive diagnostic approach is essential to differentiate EFE from other causes of myocardial thickening and heart failure in infants and young children.6,7

Clinical Evaluation: A thorough clinical history and physical examination are crucial in the evaluation of patients suspected of having EFE. Symptoms such as poor feeding, failure to thrive, tachypnea, and signs of congestive heart failure may raise suspicion for EFE.6,7

Imaging Studies:

Echocardiography: Echocardiography is the primary imaging modality used to diagnose EFE. It typically reveals thickening of the endocardium, especially in the left ventricle, with a "ground glass" appearance of the myocardium. Doppler imaging can assess for the presence of valvular regurgitation or intracardiac shunting.7,8

Cardiac Magnetic Resonance Imaging (MRI): Cardiac MRI can provide detailed information about the myocardial tissue, including the extent of fibroelastic thickening. It can also help differentiate EFE from other causes of myocardial thickening, such as hypertrophic cardiomyopathy.7,8

Electrocardiography (ECG): ECG may show nonspecific changes, such as ST-T wave abnormalities or arrhythmias, which can be seen in patients with EFE.7

Endomyocardial Biopsy: Although invasive, endomyocardial biopsy remains the gold standard for diagnosing EFE. Histological examination typically reveals fibroelastic thickening of the endocardium, with variable infiltration of inflammatory cells.8

Genetic Testing: In cases where EFE is suspected to be part of a genetic syndrome, genetic testing may be warranted to identify specific mutations associated with EFE.8

Differential Diagnosis: EFE should be differentiated from other causes of myocardial thickening and heart failure, such as hypertrophic cardiomyopathy, viral myocarditis, and storage disorders.8

Multidisciplinary Approach: Given the complexity of diagnosing EFE, a multidisciplinary team, including cardiologists, geneticists, and pathologists, may be necessary to establish a definitive diagnosis and guide management.8

Diagnosing EFE requires a comprehensive approach, incorporating clinical evaluation, imaging studies, and, in some cases, invasive testing. Early recognition and diagnosis are crucial to initiate appropriate management and improve outcomes in patients with EFE.8

## TREATMENT OF ENDOCARDIAL FIBROELASTOSIS

Endocardial fibroelastosis (EFE) poses significant challenges in terms of treatment, largely due to its rarity and the limited

understanding of its pathogenesis. Management strategies for EFE focus on symptom relief, preventing complications, and, in severe cases, considering heart transplantation.9,10

Medical Management

Heart Failure Management: Pharmacological interventions such as diuretics, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and inotropic agents may be used to manage heart failure symptoms and improve cardiac function.9,10

Arrhythmia Management: Antiarrhythmic medications may be prescribed to manage ventricular and atrial arrhythmias commonly seen in patients with EFE.9,10

Surgical Intervention:

Valvular Surgery: Patients with EFE may develop valvular regurgitation due to the involvement of the endocardium. Surgical repair or replacement of the affected valves may be necessary in some cases.9,10

Arrhythmia Surgery: For patients with refractory arrhythmias, surgical interventions such as implantation of an implantable cardioverter-defibrillator (ICD) or catheter ablation may be considered.9,10

Advanced Therapies:

Extracorporeal Membrane Oxygenation (ECMO): In cases of severe heart failure or cardiogenic shock, ECMO may be used as a bridge to recovery or heart transplantation.

Mechanical Circulatory Support (MCS): Ventricular assist devices (VADs) may be considered in patients with end-stage heart failure awaiting heart transplantation.9,10

Heart Transplantation:

Indications: Heart transplantation may be considered in patients with EFE who have refractory heart failure or severe ventricular arrhythmias that are not amenable to other therapies.

Considerations: Due to the rarity of EFE, careful consideration is needed when selecting candidates for heart transplantation, weighing the potential benefits against the scarcity of donor organs.11

Long-Term Management:

Follow-Up: Regular follow-up with a multidisciplinary team, including cardiologists, geneticists, and transplant specialists, is essential for monitoring disease progression and managing complications.12

Genetic Counseling: For patients with EFE associated with genetic syndromes, genetic counseling may be beneficial to assess the risk of recurrence in future pregnancies.12

The treatment of EFE is challenging and often requires a multimodal approach, including medical management, surgical interventions, and consideration of advanced therapies such as heart transplantation. Early diagnosis and prompt initiation of appropriate treatment are essential to improve outcomes in patients with EFE.13,14

## CONCLUSION

In conclusion, endocardial fibroelastosis (EFE) is a rare myocardial disorder characterized by the abnormal accumulation of collagen and elastin fibers in the endocardium, predominantly affecting the left ventricle. Despite its rarity, EFE can have profound implications for affected individuals, particularly infants and young children, leading to symptoms of congestive heart failure, arrhythmias, and, in severe cases, sudden cardiac death.

The diagnosis of EFE requires a high index of suspicion, as its clinical presentation can mimic other more common causes of myocardial thickening and heart failure in pediatric patients. Echocardiography is typically the first-line imaging modality used to diagnose EFE, although cardiac MRI and endomyocardial biopsy may also be employed for confirmation.

Management of EFE is challenging and often requires a multidisciplinary approach, involving cardiologists, cardiac surgeons, geneticists, and transplant specialists. Treatment strategies focus on alleviating symptoms, managing complications, and improving cardiac function. Medical therapy with diuretics, ACE inhibitors, beta-blockers, and inotropic agents may be used to manage heart failure and arrhythmias. Surgical interventions such as valvular surgery and arrhythmia surgery may be necessary in some cases. Advanced therapies including ECMO, VADs, and heart transplantation may be considered for patients with severe disease.

Overall, the prognosis of EFE varies depending on the extent of myocardial involvement, the presence of associated anomalies, and the age at diagnosis. Early recognition and prompt initiation of treatment are crucial to improving outcomes and quality of life for patients with EFE. Further research is needed to better understand the pathogenesis of EFE, identify novel treatment targets, and improve long-term outcomes for affected individuals.

## REFERENCES

I. Ozdemir D, Cortopassi IO, McNamara RL. An illustrative case of endocardial fibroelastosis and recalcitrant intracardiac thrombosis: a case report. Thromb J. 2019;17:8.

II. Chan JL, Rosing DR, Klion AD, Horvath KA. Surgical management of adult endocardial fibroelastosis. J Thorac Cardiovasc Surg. 2017 Nov;154(5):e81-e84

III. Zhang H, Huang X, Liu K, Tang J, He L, Pu W, Liu Q, Li Y, Tian X, Wang Y, Zhang L, Yu Y, Wang H, Hu R, Wang F, Chen T, Wang QD, Qiao Z, Zhang L, Lui KO, Zhou B. Fibroblasts in an endocardial fibroelastosis disease model mainly originate from mesenchymal derivatives of epicardium. Cell Res. 2017 Sep;27(9):1157-1177.

IV. Weixler V, Hammer PE, Marx GR, Emani SM, Del Nido PJ, Friehs I. Flow disturbances and progression of endocardial fibroelastosis - a case report. Cardiovasc Pathol. 2019 Sep-Oct;42:1-3.

V. Ma F, Zhou K, Shi X, Wang X, Zhang Y, Li Y, Hua Y, Wang C. Misdiagnosed anomalous left coronary artery from the pulmonary artery as endocardial fibroelastosis in infancy: A case series. Medicine (Baltimore). 2017 Jun;96(24):e7199.

VI. .Hodgson S, Child A, Dyson M. Endocardial fibroelastosis: possible X linked inheritance. J Med Genet. 1987 Apr;24(4):210-4.

VII. Brady AN, Shehata BM, Fernhoff PM. X-linked fetal cardiomyopathy caused by a novel mutation in the TAZ gene. Prenat Diagn. 2006 May;26(5):462-5.

VIII. .Aherrahrou Z, Schlossarek S, Stoelting S, Klinger M, Geertz B, Weinberger F, Kessler T, Aherrahrou R, Moreth K, Bekeredjian R, Hrabě de Angelis M, Just S, Rottbauer W, Eschenhagen T, Schunkert H, Carrier L, Erdmann J. Knock-out of nexilin in mice leads to dilated cardiomyopathy and endomyocardial fibroelastosis. Basic Res Cardiol. 2016 Jan;111(1):6.

IX. Weixler V, Marx GR, Hammer PE, Emani SM, Del Nido PJ, Friehs I. Flow disturbances and the development of endocardial fibroelastosis. J Thorac Cardiovasc Surg. 2020 Feb;159(2):637-646.

X. Xu X, Friehs I, Zhong Hu T, Melnychenko I, Tampe B, Alnour F, Iascone M, Kalluri R, Zeisberg M, Del Nido PJ, Zeisberg EM. Endocardial fibroelastosis is caused by aberrant endothelial to mesenchymal transition. Circ Res. 2015 Feb 27;116(5):857-66.

XI. Lurie PR. Changing concepts of endocardial fibroelastosis. Cardiol Young. 2010 Apr;20(2):115-23.

XII. Nield LE, Silverman ED, Taylor GP, Smallhorn JF, Mullen JB, Silverman NH, Finley JP, Law YM, Human DG, Seaward PG, Hamilton RM, Hornberger LK. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation. 2002 Feb 19;105(7):843-8.

XIII. Raboisson MJ, Fouron JC, Sonesson SE, Nyman M, Proulx F, Gamache S. Fetal Doppler echocardiographic diagnosis and successful steroid therapy of Luciani-Wenckebach phenomenon and endocardial fibroelastosis related to maternal anti-Ro and anti-La antibodies. J Am Soc Echocardiogr. 2005 Apr;18(4):375-80.

XIV. Harris LC, Nghiem QX. Cardiomyopathies in infants and children. Prog Cardiovasc Dis. 1972 Nov-Dec;15(3):255-87.